TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05931627

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients undergoing ACL reconstruction with or without a tourniquet
Description: Patients undergoing ACL reconstruction with or without a tourniquet
Study: NCT06347029

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow mediated dilatation test
Description: The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow mediated dilatation test
Description: The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.
Study: NCT06054971

Intervention type: OTHER
Intervention: Remote Administration of NSAA
Description: Remote Administration of NSAA

Intervention type: OTHER
Intervention: Remote Administration of NSAA
Description: Remote Administration of NSAA
Study: NCT06347029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow mediated dilatation test
Description: The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow mediated dilatation test
Description: The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.
Study: NCT05403060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALIADA: Alimentación, Adolescencia y Ambiente
Description: The objective of the educational nutritional intervention is to promote in adolescents an increase in their consumption of vegetables and fruits and a decrease in their consumption of ultra-processed foods, through the application of the TSC constructs, with the use of education by pairs as the main strategy (peer leaders). It lasts two months, includes three exclusive sessions for peer leaders and five sessions for all participants, where the leaders, together with the researchers, will lead the activities of the sessions, as well as a general event for all high school students. Intervention activities include: electronic presentations, videos, food preparation and label reading workshops, individual and team reflection activities, goal setting and monitoring, board games, contests, among others. In addition, each participant is given a workbook, which contains key messages and activities for each educational session.
Study: NCT05982704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tixagevimab/cilgavimab 150+150 mg
Description: Administration of tixagevimab/cilgavimab at a dose of 150+150 mg in patients with moderate/severe coronavirus infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tixagevimab/cilgavimab 300+300 mg
Description: Administration of tixagevimab/cilgavimab at a dose of 300+300 mg in patients with moderate/severe coronavirus infection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regdanvimab
Description: Administration of regdanvimab at a dose of 40 mg/kg body weight in patients with moderate/severe coronavirus infection.
Study: NCT05024422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: Administration of Cabergoline (one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridoxine
Description: Administration of Pyridoxine (200 mg X 3 per day for a week)
Study: NCT05854030

Intervention type: DIAGNOSTIC_TEST
Intervention: collect plasma samples and clinical features
Description: 8ml of peripheral blood need to be collected from pre- and post-treatment advanced pulmonary squamous carcinoma separately

Intervention type: DIAGNOSTIC_TEST
Intervention: collect plasma samples and clinical features
Description: 8ml of peripheral blood need to be collected from pre- and post-treatment advanced pulmonary squamous carcinoma separately
Study: NCT04853147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl
Description: palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, fosaprepitant 150mg dissolved in 0.9% NaCl 150ml, iv.drip,

Intervention type: DRUG
Group type: OTHER
Intervention: palonosetron, dexamethasone, and 0.9% NaCl
Description: palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, 0.9% NaCl 150ml, iv.drip,
Study: NCT05068674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells
Description: 50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells
Description: 150M cells delivered in a dose of 15M cells per injection over 10 injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells
Description: 300M cells delivered in a dose of 30M per injection over 10 injections
Study: NCT04732429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HST5040
Description: Liquid solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Liquid solution
Study: NCT05893680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group to play online games
Description: Playing games in children is one of the non-pharmacological pain relief methods. In this study, the effect of playing an online game on pain level in children who underwent orthopedic surgery for pain management after the surgery was measured.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group that received cold application
Description: Previous studies have demonstrated that cold application has anti-inflammatory, muscle spasm reducing, and pain relieving properties. In this study, the effect of cold application on pain level in children who underwent orthopedic surgery was investigated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group that received placebo (PHYSIOLOGICAL SALINE ISOTONIC 9 mg/ml AMPULE)
Description: The placebo effect has been demonstrated in various studies today. Some of these studies describe placebo analgesia. In this study, the placebo analgesic effect was investigated, and the child and parent were told that an analgesic was applied, but instead 2 cc of PF 0.9% ISOTONIC SODIUM CHLORIDE solution was intravenously administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group that played an online game and received cold application at the same time
Description: To investigate the combined effect of online gaming and cold application as two separate non-pharmacological interventions, both interventions were applied together in this group
Study: NCT05884229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-operative analgesia guided by SPI
Description: In the SPI-guided group, when SPI is higher than 50 for the first time and for more than 3 minutes, we will administer 1,0 μg/kg of fentanyl LBW. When SPI is again higher than 50 and for more than 5 minutes, we will re-administer 1,0 μg/kg of fentanyl LBW. We will repeat until SPI is between 20-50.
Study: NCT04904081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
Study: NCT05191641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized nursing care
Description: Individualized nursing care based on the Professional Values Model for parents of pediatric oncology patients
Study: NCT05929508

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic Preconditioning
Description: A blood pressure cuff will be placed on the thigh of the intact/sound limb to restrict blood flow to the lower extremity for 5 minutes and then deflated for 5 minutes to allow for normal blood flow on a cycle for 50 minutes (5 times).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ischemic Preconditioning
Description: A blood pressure cuff will be placed on the thigh of the intact/sound limb to restrict blood flow to the lower extremity for 5 minutes and then deflated for 5 minutes to allow for normal blood flow on a cycle for 50 minutes (5 times).
Study: NCT04826328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX301
Description: FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX301
Description: FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX301
Description: FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX301
Description: FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single peripheral nerve injection
Study: NCT06347029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow mediated dilatation test
Description: The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flow mediated dilatation test
Description: The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.
Study: NCT04999956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic navigation surgery
Description: immediate implant placement using dynamic navigation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: freehand surgery
Description: immediate implant placement using freehand surgery
Study: NCT05460429

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Description: The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Description: The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Description: The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Description: The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Description: The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.
Study: NCT05381181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-UCART
Description: A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
Study: NCT05144438

Intervention type: DIAGNOSTIC_TEST
Intervention: Toxseek test
Description: Hair taking
Study: NCT05441371

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste; Paradontax
Description: Comparison of Paradontax toothpaste anti-plaque abality versus regular toothpaste

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste; Paradontax
Description: Comparison of Paradontax toothpaste anti-plaque abality versus regular toothpaste
Study: NCT04598932

Intervention type: DEVICE
Intervention: Brillouin microscopy
Description: The Brillouin clinical instrument is comprised of three parts: a human interface, a laser-scanning confocal microscope, and an etalon-based spectrometer. The human interface is a modified ophthalmic slit-lamp instrument with chin support and headrest. The light source is a single longitudinal mode CW laser at 780 nm. A polarizing beam splitter and quarter-wave plate assembly sends the laser beam to the human interface. To focus light into the eye, a long-working distance microscope objective is used. Brillouin scattered light from the eye is collected with a single-mode optical fiber. For spectral analysis, a two-stage VIPA-etalon spectrometer configured with the cross-axis cascade principle and the spectrum is measured on a EM-CCD camera.
Study: NCT05889585

Intervention type: OTHER
Group type: OTHER
Intervention: quality of life questionnaire
Description: EORTC-QLQ C-30 questionnaire The Impact of Events Scale (IES-R) Multi-Dimensional Fatigue Inventory The EORTC-QLQ C-30 Vers. 3

Intervention type: OTHER
Group type: OTHER
Intervention: quality of life questionnaire
Description: EORTC-QLQ C-30 questionnaire The Impact of Events Scale (IES-R) Multi-Dimensional Fatigue Inventory The EORTC-QLQ C-30 Vers. 3

Intervention type: OTHER
Group type: OTHER
Intervention: quality of life questionnaire
Description: EORTC-QLQ C-30 questionnaire The Impact of Events Scale (IES-R) Multi-Dimensional Fatigue Inventory The EORTC-QLQ C-30 Vers. 3
Study: NCT04686279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Douche
Description: 660 mg TFV in 125 mL hypo-osmolar solution
Study: NCT06351644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 123300
Description: dosed starting at 200 mg of ON 123300 (NARAZACICLIB) daily for four weeks. Dose levels will be 160 mg, 200 mg, 240 mg, 280 mg, 320 mg. Treatment cycles will be four weeks long.~ON 123300 (NARAZACICLIB) is available as an oral formulation ON 123300 (NARAZACICLIB) monolactate capsules (containing 40 mg free base) and is provided in 120 cc high-density polyethylene (HDPE) bottles with child-resistant closures containing 30 hard gelatin capsules. ON 123300 (NARAZACICLIB) is also available in tablet form. The tablets are 40 mm (oblong) and 120 mg (round). Either form, capsules or tablets, may be used in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Weekly oral dexamethasone 20mg
Study: NCT04705363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectal Features Varied
Description: Participants will randomized to interact with a VHA that speaks either Standardized American English, a low level of African American English, or a high level of African American English

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Intervention
Description: Participants will randomized to either receive a video introduction from the voice actor or receive no introduction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VHA with no voice
Description: virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide you through the interaction. No voice will accompany the photos or text.
Study: NCT06529731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b
Description: ACTIMMUNE/Interferon gamma-1b is a single-chain polypeptide containing 140 amino acids that is produced by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the recombinant protein. Interferon gamma-1b is part of a drug regimen used to treat Chronic Granulomatous Disease, or CGD. CGD is a genetic disorder, usually diagnosed in childhood, that affects some cells of the immune system and the body's ability to fight infections effectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Leukocyte Infusion (DLI)
Description: Donor lymphocyte infusion is a procedure that transfers healthy white blood cells (lymphocytes) from a bone marrow or stem cell donor to a recipient's blood. An infusion of healthy lymphocytes helps the recipient's immune system get rid of remaining cancer cells if they have a relapse after a bone marrow or stem cell transplant for blood cancer.
Study: NCT05890352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo optional collection of blood
Study: NCT05920525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: A specific device will be used to stimulate the remodeling procedures in the alveolar bone.
Study: NCT05672498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chinese Medicine Formulation
Description: The TCM Treatment Group：The patient are given a traditional Chinese medicine formulation, taking 150 ml of liquid medicine every morning and evening for 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Treatment
Description: Placebo Treatment Group:The patient are given placebo, taking 150 ml of liquid placebo every morning and evening for 7 days. All medications and placebo are packed identically in packing bags with the same labeling form.
Study: NCT05920525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional retraction of the front upper teeth
Description: The retraction will be performed using coil springs which will help in moving the anterior teeth backward without the need to employ any additional procedure or device to accelerate this movement.
Study: NCT06396416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Weight Management Coaching
Description: Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.
Study: NCT06481579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-A12
Description: IVX-A12 IM injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed RSV Vaccine
Description: Licensed RSV Vaccine IM injection.
Study: NCT05441618

Intervention type: DEVICE
Intervention: Lyoplant®
Description: replacement and extension of connective tissue structures in neurosurgery
Study: NCT06376981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injection
Description: An injection of 2 ml of Acid hyaluronic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Description: An injection of 1 ml of corticosteroids

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid injection
Description: An injection of 1 ml of corticosteroids

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: An injection of 2 ml of placebo (physiological serum)
Study: NCT05827874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap
Description: Tdap will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Tdap
Description: Tdap will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPSV23
Description: PPSV23 will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PPSV23
Description: PPSV23 will be administered as an IM injection.
Study: NCT06617234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led Intervention Program
Description: Nurse-led Intervention Program: This intervention consists of a face-to-face educational session led by a nurse, focusing on the importance of cardiac rehabilitation. The session lasts 15-20 minutes and is tailored to the patient's medical condition and lifestyle, with follow-up reminders and personalized guidance for rehabilitation participation.~LINEbot Automated Robot System: This intervention uses the LINEbot system to send automated push notifications to participants, including educational messages, reminders for cardiac rehabilitation appointments, and health tracking prompts. Participants can log their daily health data through the system, which offers personalized advice on diet, exercise, and medication management.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LINEbot Automated Robot System
Description: Participants in this group will use the \&amp;#34;LINEbot\&amp;#34; automated robot system, which sends push notifications through the LINE app. The system delivers education messages, exercise guidance, and health tracking prompts. It provides daily reminders for cardiac rehabilitation participation, as well as customized messages on health management, such as diet, medication, and self-care. The system also allows users to log health data like blood pressure and heart rate.